Amrad shareholders stock up
Thursday, 22 July, 2004
Some of Amrad's larger shareholders are boosting their holdings in the Melbourne company (ASX:AML), as long-time Japanese investor Chugai divests itself of its 10 per cent stake in the company.
Yesterday the Queensland Investment Corporation -- a major institutional player in Australia's biotechnology sector -- filed documents with the ASX indicating that it had increased its holdings from 5.45 per cent to 10.495 per cent.
And today, the Thorney group, run by multi-millionaire Richard Pratt, said it had raised its stake in the company from 9.14 per cent to 11.88 per cent.
Chugai retains a 2.52 per cent share of the company, making $4.3 million out of the sale of its shares.
The relationship between Amrad and Chugai stretches back 10 years, over which time the Japanese company invested about $20 million into Amrad. But the joint research contract came to a natural end last year when its term expired.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
